AIM: To analyze the effect of preoperative intravitreal injection of Ranibizumab(IVR)in patients undergoing pars plana vitrectomy(PPV)for proliferative diabetic retinopathy(PDR).

METHODS:In this retrospective research, 62 patients(67 eyes)with PDR in the First Affiliated Hospital of Xinjiang Medical University from Jun. 2014 to Jun. 2015 were recruited. They were assigned to an experimental group(n=37 eyes)and a control group(n=30 eyes). The patients in experimental group were given 1 injection of IVR(Lucentis 1.0mg/0.1mL)1wk before surgery, whereas those in control group went down to surgery directly. The average operation time, iatrogenic breaks, the use of tamponade, electric coagulation, and vision increase rate were comparatively analyzed between two groups.

RESULTS:The average operation time was(91.7±20.8)min in the experimental group vs(117.6±18.6)min in the PPV group(t=-5.314,P<0.05). The rate of electric coagulation(11%)vs(47%),(χ²=8.963, P=0.006); iatrogenic breaks(5%)vs(33%),(χ²=8.789, P=0.004)and silicone oil or inert gas tamponade(27.0%)vs(53.3%),(χ²=4.828, P=0.043). The rate of visual improvement(75.7%)vs(46.7%),(χ²=5.960, P=0.022). There was no severe complication associated with surgery, such as choroidal detachment, retinal detachment and endophthalmitis.

CONCLUSION:IVR before microincision vitrectomy can effectively shorten the operation time, reduce the use of electric coagulation and intraocular tamponade, and improve the rate of visual improvement for PDR patients.